ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer

Over the past 2 years, the use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has become the standard of care for these patients. The first combination was nivolumab plus ipilimumab, which demonstrated a survival benefit over sunitinib in patients with intermediate and poor risk metastatic RCC (CheckMate-214). Shortly after, […]

read more

Sapanisertib is tolerable and shows activity in advanced kidney cancer

In a phase I study to look at the safety and tolerability of a new drug called sapanisertib, sapanisertib was well-tolerated and showed some anti-tumour activity in patients with renal cell carcinoma (RCC) and endometrial cancer. Sapanisertib is an oral, highly selective inhibitor of the mTORC1/mTORC2 receptors in advanced solid tumours. In the study, 82 […]

read more

GRANT score for predicting disease-free survival in kidney cancer

In this retrospective study conducted at various hospitals in Italy, the GRANT (GRade, Age, Nodes, and Tumour) and the UISS (University of California Los Angeles Integrated Staging System) scores were compared in 134 patients with renal cell carcinoma (RCC) who had a nephrectomy. These scores are used to predict outcomes in patients with localised RCC. […]

read more

First-line treatment of kidney cancer

These two videos with Dr Eric Jonasch from MD Anderson Cancer Center and Dr Elizabeth Plimack from Fox Chase Cancer Centre, both in the USA, explain how clinicians choose between the first-line treatments that are available for the treatment of renal cell carcinoma (RCC) and the long term control of the disease. Watch the video […]

read more

Gut microbes linked with immunotherapy response in kidney cancer

A recent study published in European Urology had shown that the diversity of microbes in the gut is associated with better outcomes in people with metastatic renal cell carcinoma (RCC) who are taking immunotherapy. There are numerous bacteria and viruses in the gut, called the microbiome. This gut microbiome is increasingly linked to health and […]

read more

Biological markers of response for kidney cancer

To date, a reliable biomarker is yet to be discovered for the response of kidney cancer patients to treatment or for prognosis. In this review paper, Dr Robert Motzer and his research group from Memorial Sloan Kettering in the USA identified a set of 26 genes whose activity correlated with progression-free survival in the combination […]

read more

Advances in systemic treatments for metastatic kidney cancer

In this video interview Professor Jens Bedke from the Department of Urology, Eberhard Karls University Tübingen in Germany discusses the transformation in the first-line treatment of renal cell carcinoma (RCC) from tyrosine kinase inhibitors (TKIs), which was the standard of care, to combination therapies. First-line treatment with a combination of an immune checkpoint inhibitor and […]

read more

Radiotherapy and zoledronic acid for the treatment of kidney cancer bone metastases

Radiotherapy is often used for the treatment of bone metastases from renal cell carcinoma (RCC). However, radiotherapy can cause a number of bone-related adverse events, such as fracture, loss of sensation and movement in the hands and feet (paraplegia), surgery or radiotherapy for local recurrence, or severe pain in bone metastases that  are resistant to […]

read more

Pembrolizumab plus axitinib combination accepted by NHS Scotland for first-line treatment of advanced kidney cancer

The Sottish Medicine Consortium (SMC) have issued a final decision to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for pemrolizumab in combination with axitinib for untreated patients with advanced or metastatic renal cell […]

read more

Microwave ablation of kidney masses

A study published in the British Journal of Urology reported the experience of one hospital with microwave ablation for suspected renal cell carcinoma (RCC). Microwave ablation is the use of extreme hot or cold (thermal ablation) to treat cancer. It uses electromagnetic waves through the skin to produce tissue-heating effects. One hundred and thirteen patients […]

read more
Showing 21 to 30 of 695 results
  TOP